BD, the Franklin Lakes medical technology company, has named a pair of new executive leaders, it announced Thursday.
The company, also known as Becton, Dickinson & Co., said Patrick Kaltenbach has been named executive vice president and chief technology officer, while Dave Hickey has been promoted to EVP and president, life sciences. Both moves are effective Jan. 1.
Kaltenbach, who joined BD as president of the Life Sciences unit in May 2018, will now be responsible for the company’s category innovation strategy and leadership of its research & development activities. He also will oversee BD’s new “Innovation and Growth Fund,” advancing its strategy and increasing its investments in priority R&D programs.
“Patrick has distinguished himself throughout nearly three decades in R&D management and business leadership, making him an ideal candidate to continue our drive toward category innovation in alignment with our strategy to ‘Grow, Simplify, and Empower,’” CEO and President Tom Polen said in a prepared statement.
He succeeds John DeFord, who is retiring at year-end as CTO. DeFord, who joined BD through its acquisition of C.R. Bard Inc. in 2017, will remain as an adviser and consultant to the company.
Meanwhile, Kaltenbach will be replaced as head of the Life Sciences unit by Hickey, currently the worldwide president of the Integrated Diagnostics Solutions business. In his new role, Hickey will oversee all of BD’s biosciences, preanalytical systems and diagnostics systems businesses. He joined BD in 2014.
“I’m confident Dave is the right successor to lead the life sciences segment at this critical time for the industry and for public health,” Polen said.
Both Kaltenbach and Hickey will report to Polen in their new roles.
